© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to February
EGFR exon 20 mutant inhibitor, oral once-daily
Breakthrough Therapy for ex20+ NSCLC (Ph. I)
from cellular screening + SBDD
Cancer Discovery, Feb. 25, 2021
ARIAD/Takeda, Cambridge, MA
4. The ARIAD/Takeda EGFR exon 20 insertion mutant (EGFRex20ins) inhibitor TAK-788 is a Breakthrough Therapy for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.